The purine metabolic gene adenosine deaminase (ADA) is expressed at high levels in a well defined spatiotemporal pattern in the villous epithelium of proximal small intestine. A duodenum-specific enhancer module responsible for this expression pattern has been identified in the second intron of the human ADA gene. It has previously been shown that binding of the factor PDX-1 is essential for function of this enhancer. The studies presented here examine the proposed roles of GATA factors in the enhancer. Site-directed mutagenesis of the enhancer's GATA binding sites crippled enhancer function in ten lines of transgenic mice, with nine of the lines demonstrating less than 1% of normal activity. Detailed studies along the longitudinal axis of mouse small intestine indicate that GATA-4 and GATA-5 mRNA levels display a reciprocal pattern, with low levels of GATA-6 throughout. Interestingly, gel shift studies with duodenal nuclear extracts showed binding only by 
INTRODUCTION
The mammalian intestinal epithelium has a complex, but highly defined, architecture.
The primary components of this architecture in the small intestine are the crypt and villus.
Within the lower parts of the crypts are anchored stem cells that serve as precursors of all four cell types populating the continuously regenerating epithelium (48, 49). After undergoing cell division and the initiation of differentiation in the crypts, the immature cells undergo a bipolar migration. Enterocytes, goblet cells, and enteroendocrine cells migrate as a linear column up the surface of the villus. Paneth cells migrate in the opposite direction toward the base of the crypt.
The function of each of these various differentiated cell types in the intestinal epithelium is defined principally by the set(s) of genes that are expressed in that cell type. Therefore profiles of expression exist along the crypt-villus axis that are dependent on cell type, differentiation status, and cell migration. In addition, significant variations in gene expression within the same cell type are observed along the cephalocaudal (horizontal) axis of the intestine. These functional variations are established and maintained in the adult even though the intestinal epithelium undergoes a continuous renewal. It is proposed that a discrete regulatory network controls these processes. This interrelated network of transcription factors and cis-acting elements that specify and regulate gene expression along the various physical and temporal axes of the small intestine is just now beginning to be sorted out (13, 53). The analysis of promoters and enhancers that specify the intestinal expression of individual genes can contribute significantly to that process.
The adenosine deaminase (ADA) gene has a complex, highly regulated tissue-specific pattern of expression. It is expressed in all mammalian tissues, but the expression levels vary over a range of several thousand-fold and undergo significant changes in various tissues and cell 4 types in a developmentally specific manner (6). A number of distinct genomic regions (regulatory modules) that control ADA tissue expression in mice and humans have been identified and characterized (2, 9, 15, 50, 57, 60). These modules contain tissue-specific enhancers that bind a variety of transcription factors, which collaborate to control chromatin structure and activate ADA gene transcription in distinct cell types. One cell type that exhibits very high levels of ADA expression is the absorptive enterocyte of the duodenal epithelium in the small intestine. This high level expression in enterocytes is observed only in the duodenum and only in enterocytes that have migrated past the crypt-villus junction onto the villus.
Developmentally, this enhancer-dependent high level activation is first observed in mice at the suckling-weanling transition and continues into adulthood. Gene ablation studies have shown that ADA expression is essential for duodenal integrity and viability (37, 59). Transgenic mouse studies have been used to identify and map an enhancer that activates high-level ADA expression specifically in the duodenum (15-17). The enhancer can activate expression that recapitulates endogenous gene activation exactly along three distinct axes: the cephalocaudal (anteriorposterior) axis, the crypt-villus differentiation axis, and the axis of developmental time (15, 16).
In initial footprinting studies, a number of transcription factors were indirectly implicated in enhancer function (15) . Recent studies have shown that the factor PDX-1 is critical for enhancer function (17). The present study examines proposed roles for the GATA family of transcription factors in the enhancer's function.
Each member of the GATA family of transcription factors has a highly conserved DNA binding domain containing two zinc fingers that recognizes the consensus sequence WGATAR (27, 36). Six GATA factors have been identified in vertebrates, and these can be divided into two subfamilies, GATA-1, -2, and -3 and GATA-4, -5, and -6. The latter subfamily is expressed in various tissues of mesodermal and endodermal origin, including heart, liver, lung, gonad, and gut, where they play critical roles in regulating tissue-specific gene expression (40).
Targeted disruption of the GATA-4, -5, and -6 mouse genes have identified roles for these factors in formation of heart, endoderm, lung epithelium, gastric epithelium, and genitourinary tract (25, 28, 30, 41, 42, 46, 51) . In adult mice, GATA-4, GATA-5, and GATA-6 are all expressed in epithelium of the small intestine (1, 40, 44) . Initial analysis of GATA factor expression in the gastrointestinal epithelium of embryonic chicks and young hatchlings led to the proposal of both distinct (20) and overlapping (31) functions for GATA-4, -5, and -6 in that epithelium. GATA factors have been implicated in the intestine-specific regulation of promoter function for several genes, including sucrase-isomaltase (8, 29, 53), rat and human lactasephlorizin hydrolase (18, 19, 29, 54), and intestinal fatty-acid binding protein (20) . In the studies presented here, transgenic mouse experiments were used to identify a crucial role for GATA binding sites in the in vivo function of the duodenum-specific enhancer of the ADA gene.
Additional studies with duodenal nuclear extracts indicate that these sites are bound principally, if not exclusively, by GATA-4.
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EXPERIMENTAL PROCEDURES
Oligonucleotides. Oligonucleotides were synthesized at the University of Cincinnati DNA core facility and are as shown in Figure 1B or as described below. Oligonucleotides G2 and PDX-1 have been previously published as oligonucleotides FP 2C and P1 respectively (17).
Oligonucleotide consensus sequences for AP-1 CGCTTGATGACTCAGCCGGAA and GATA CACTTGATAACAGAAAGTGATAACTCT are as indicated in the Santa Cruz Biotechnology catalog. Probe oligonucleotides for EMSA experiments were gel purified as reported (17).
Transient transfection. The GATA expression vector plasmids, pcDNA GATA-4, pcDNA GATA-5, and pcDNA GATA-6 were the generous gift of Jeffery Molkentin (Cincinnati Children's Hospital Medical Center). The human adenocarcinoma cell line CaCo-2 (ATCC#HTB 37) was cultured in DMEM with 10% fetal bovine serum, 0.05 units penicillin and 0.05 mg/ml streptomycin. DNA was introduced into cells at 70-80% confluency by Life Technologies (Carlsbad, CA) LIPOFECTIN transfection according to the manufacturer's protocol using 27.7 ml of LIPOFECTIN and 2 mg of DNA per 100 mm dish. Media was replaced 16 and 24 hours after transfection. 64 hours after transfection cells were harvested and nuclear extracts prepared.
Extract preparation. Mouse duodenal nuclear extracts were prepared as previously described (17). Transfected cells were washed with PBS at 37°C and then scraped into 1 ml of PBS at 4°C, pelleted, washed again with 1 ml of PBS at 4°C and repelleted. Cells were resuspended in 2 packed cell volumes of lysis buffer (10mM HEPES-KOH pH 7.9, 10mM KCl, 0.1mM EDTA, 1.5mM MgCl 2 , 0.2% NP-40, 1mM DTT, and 0.5mM PEFABLOC), vortexed for 5 minutes and incubated 10 minutes on ice. Nuclei were pelleted, washed once with lysis buffer, and pelleted again. The nuclear pellet was resuspended in 100 ml of extraction buffer (20mM 7 HEPES-KOH pH 7.9, 420mM NaCl, 0.1mM EDTA, 1.5mM MgCl 2 , 25% glycerol, 1mM DTT, and 0.5mM PEFABLOC). Samples were incubated on ice for 20 minutes and vortexed every 10 seconds. Samples were spun at 15,000 RPM, 4°C for 20 minutes in a microcentrifuge. The supernatant was removed and stored at -70°C.
Electrophoretic mobility shift assay (EMSA). 10mg of mouse duodenal nuclear extract or 2 ul of CaCo-2 transfected nuclear extract was used for each gel shift reaction. Normal rabbit IgG and antibodies to GATA-4, -5, and -6 were purchased from Santa Cruz Biotechnology.
Supershift EMSAs were incubated overnight at 4°C.
Site-directed mutagenesis and transgene preparation. All enzymes were from New England Biolabs (Beverly, MA) unless otherwise stated. pALTER 319+ (17) was used as template for mutagenesis reactions using the Promega Altered Sites protocol (Madison, WI).
GATA mutation oligonucleotides were prepared at the University of Cincinnati DNA core f a c i l i t y w i t h t h e f o l l o w i n g s e q u e n c e s
GCTCCATAAATGTCACTTAATGAGTATATTCTTATTAATTGGAGC (G2m-ext), and GGGGTGAAACCTCTTGGCTTAAGTCTGCCTGGCCTTTGC (G3m-ext). Successive rounds of mutagenesis were used to introduce each mutation shown in Figure 1B into the enhancer core fragment. The mutated BsiWI enhancer fragment containing the GATA site mutations was sequenced in its entirety to ensure fidelity of both the mutated sites and the remaining sequences of the enhancer. The GATA-mutated enhancer fragment was liberated with
BsiWI and ligated into BsiWI cut p5'acba L117DD (15) to generate the plasmid p5'acba L117
GATA mut. In situ hybridization. In situ hybridization experiments were performed using CATspecific RNA probes on transgenic duodena from wild type line 10 or GATA mutant line 1 as described previously (15, 16).
RNA isolation and Northern analysis. Stomach, small intestine, cecum, colon, liver, and heart were isolated from five 7 week-old non-transgenic FVB/N mice. The small intestine was subdivided further into 2 cm segments and equivalent segments were pooled. The poly(A+) fraction of RNA was isolated as described previously (4). Samples containing 1mg of poly(A+)
RNA were electrophoresed, blotted, and Northern analysis performed using the RNA anti-sense probes described below. pcDNA GATA-4 was digested with EagI, filled with T4 DNA polymerase, and subsequently digested with EcoRI. The 436bp fragment was isolated and ligated to SmaI-EcoRI cut pGEM4Z (Promega). The resulting plasmid pGEM-G4 was linearized with EcoRI and used as template for anti-sense RNA probe synthesis using T7 RNA polymerase. pcDNA GATA-5 was digested with NcoI, filled with T4 DNA polymerase, and then digested with HindIII. A 389bp fragment was isolated and ligated to SmaI-HindIII digested 9 pGEM-4Z. The resulting plasmid, pGEM-G5.2, was linearized with HindIII and used as template for radioactive anti-sense RNA probes synthesized with SP6 RNA polymerase. pcDNA GATA-6 was digested with AccI, filled with T4 DNA polymerase, and then digested with SacI.
A 528bp fragment was isolated and ligated to SmaI-SacI digested pGEM-4Z to form pGEM-G6.
pGEM-G6 was linearized with HindIII and used as template for radioactive anti-sense probe synthesis using SP6 RNA polymerase. Probes were synthesized and stripped as directed in Ambion Strip-EZ kit (Austin,TX). GATA-4/-5/-6 mRNA was quantitated using a phosphorimager (Molecular Dynamics) and normalized to both the background and the specific activity of the probe.
DNase I hypersensitivity. Transgenic mice were bred to homozygosity. Duodena were isolated from four adult mice and nuclei prepared as described previously (17) with the following exceptions: Buffers A and B were supplemented only with 80mM PMSF and 1.0mM DTT and N-acetyl-L-cysteine was omitted. The nuclear pellet was resuspended in 5 ml cold nuclei wash buffer (20 mM HEPES-KOH pH 7.9, 13.3 mM NaCl, 13.3 mM KCl, 0.133 mM spermidine, 0.5 mM spermine, 2mM EDTA, 0.5 mM EGTA, and 3mM MgCl 2 ) and the number of nuclei was estimated using a hemacytometer. DNase I treatment, DNA isolation, and Southern blotting were performed as described previously (16) except that each sample was treated with 9 units of DNase I for 10 minutes at 30°C.
RESULTS
Duodenum-specific enhancer contains 3 sites that bind GATA-4. The duodenum-specific enhancer region is located within the second intron of the human ADA gene ( Figure 1A ). Two consensus GATA recognition sequences were observed within the footprinted regions of this enhancer. A third consensus match sequence is also present in the enhancer core, but was not observed to footprint (perhaps due to its location adjacent to the end of the DNA strand used for these experiments). To assess the binding ability of these sites, oligonucleotides corresponding to these sequences (G1, G2, and G3 in Figure 1B To confirm the integrity of the antibodies used in Figure 2C , CaCo-2 cells were transfected independently with the GATA expression vectors pcDNA-GATA-4, pcDNA-GATA-5, and pcDNA-GATA-6. Nuclear extracts were prepared from transfected cells and used in EMSA experiments ( Figure 2D ). Using radiolabeled GATA consensus oligonucleotide as a probe, a shifted band was produced with each GATA transfected extract (Lanes 1, 5, and 9).
Addition of an excess of unlabelled GATA consensus oligonucleotide prevented formation of this complex (Lanes 2, 6, and 10) thereby confirming that these complexes do contain GATAbinding proteins. Reactions incubated in the presence of the anti-GATA-4 (Lane 4), anti-GATA-5 (Lane 8) and anti-GATA-6 (Lane 12) antibodies were each able to produce the expected supershift, while a non-specific antibody (Lanes 3, 7, and 11) did not. Residual GATA complex that does not supershift in Lanes 4, 8, and 12 is the result of endogenous GATA-4 and GATA-6 expression in CaCo-2 cells (data not shown). The ability of each antibody to recognize its cognate protein allows us to conclude that the duodenal nuclear extracts produced do indeed contain only GATA-4 protein.
GATA-4 complexes do not form on the mutated oligonucletides G1m, G2m and G3m.
Experiments were carried out to identify sequence changes that specifically eliminate GATA binding in vitro. Various base pair changes were introduced into each oligonucleotide sequence and tested in EMSA experiments for loss of GATA binding (data not shown). The optimal mutations are shown as bold lower case letters in the sequences designated as G1m, G2m, and G3m in Figure 1B . EMSA experiments using the wild type and mutated oligonucleotides as probe are shown in Figure 2B . Once again the slowly migrating complex, labeled as GATA, is 
GATA-mutant transgenic mice have decreased duodenal CAT activity. The mutations
that resulted in loss of GATA binding (G1m, G2m, and G3m) were used in transgenic studies to assess the role these factors play in the enhancer function in vivo. Mutations were introduced into the enhancer core such that all the GATA sites within the enhancer core were ablated. This mutated enhancer core was then used to replace the wild type enhancer core within a 13kb
intragenic ADA fragment maintaining the same position and orientation in each. Wild type (wt) and GATA mutant transgenes each contain analogous DNA fragments are shown in Figure 1A .
These include a 3.8 kb human ADA promoter/5' flanking segment attached to the CAT coding sequence, as well as the 13 kb fragment containing the enhancer and its core. The only relevant sequence differences between these transgenes is the mutations described above. Ten independent transgenic lines were produced and analyzed for the GATA mutant.
A minimum of two adult F 1 mice were analyzed for CAT activity in various tissues for each independent transgenic line. Protein concentration and copy number were also assessed.
All transgenic CAT activities reported are normalized to both protein concentration and transgene copy number and are expressed in units of pmol/hr/100 mg of protein/transgene copy and are shown in Figure 3 and Table 1 . CAT activities for the wild type transgene were previously reported (15-17) and are included here for comparison only. As shown in Figure 3 , duodenal CAT activity/copy in mice containing the wild type 13kb fragment range from 1,400-31,000 units with a mean activity of 9,100 units. In every line, duodenum is the site of highest transgene activity and is usually 100-1000-fold greater than the next highest tissue ( Table 1) .
Loss of GATA binding within the duodenal enhancer in vivo had a dramatic effect on the levels of transgene expression. Duodena from mice containing the GATA-mutated enhancer contained significantly reduced transgene activity compared to wild type duodena (Figure 4 ).
Duodenal CAT activity/copy in these mice range from 0.4-780 with a mean activity of 90 units. A/P CAT distribution is altered in the GATA mutant transgenic duodena. Along the anterior posterior (A/P) axis of the small intestine, high-levels of endogenous mouse ADA are restricted to the region between the pyloric sphincter and a point 4-5 cm distal to it (16). The transgene containing the wild type enhancer exhibits an identical pattern along the A/P axis, with high-level CAT activity limited to the first 4-5 cm of the small intestine as shown in Figure 4A (16). In order to examine the effects of the GATA site mutations on the expression of the transgene in vivo along the A/P axis, small intestines from GATA mutant line 1 were analyzed segmentally ( Figure 4B ). The intestines were cut into 2 cm sections beginning at the pyloric sphincter and each segment was assayed for transgene activity. In these mice essentially all the activity is limited to the first 2 cm of the small intestine. Therefore, not only is the overall duodenal activity significantly lower in transgenic mice containing the GATA-mutated enhancer compared to the wild type, but the region of the small intestine expressing the transgene at highlevels is reduced and limited to the very most anterior portion of the small intestine. Crypt-villus distribution has not changed qualitatively from the wild type, in that high-level expression is still limited to the villous epithelium and absent from the crypts and the mucosa.
GATA mutant duodena have decreased numbers of cells on the villus that
However, the total number of cells expressing the transgene at high-levels is significantly reduced resulting in a mosaic pattern of expression ( Figure 5D and E). Figure 5B and the enlarged subregion in Figure 5C show ISH performed on a transgenic littermate to the mouse used for Panel D-F. In this mouse the loss of cells expressing high levels of the transgene is even more dramatic. Only 3-5 cells per cross-section express the transgene (Marked by arrows in 5C).
These few cells do appear to express the transgene quite robustly at levels similar to those 16 observed with the wild type enhancer transgene. This suggests that the reduced activity observed in the GATA mutant enhancer mice is not the result of decreased transgene expression in all cells, but rather a decrease in the total number of cells able to express at high levels.
GATA-4 is the predominant GATA family member in the duodenum. EMSA studies suggested that only GATA-4 protein was present in detectable amounts in the adult mouse duodenum. The relative cephalocaudal expression and distribution of the GATA factors within mouse small intestine has not yet been defined. To investigate this further, Northern analysis was performed to examine the distribution of each GATA factor along the length of the small intestine and in other tissues. Five adult FVB/N mice were sacrificed. Heart, stomach, liver, cecum, colon and small intestine were harvested. The small intestines were divided into 2 cm segments and equivalent segments from the five mice were pooled. The poly(A+) RNA was isolated and 1 mg of each was electrophoresed, blotted and hybridized to labeled anti-sense GATA-4, GATA-5, or GATA-6 RNA probes ( Figure 6A ). The results agree in general with previous studies that investigated GATA expression in liver, heart, and the small intestine (1, 8, 44, 45) . Appropriately sized mRNA were observed with each probe. A 4 kb GATA-4 mRNA was observed in heart, stomach, and all the small intestine samples. It was absent from cecum and colon and present in only small amounts in liver. Two distinct GATA-5 mRNA species, a 3.2 kb and a 1.8 kb mRNA were observed. Both species had been observed previously when using a probe to the open reading frame of GATA-5 such as the one used in this experiment (45).
Both mRNA were found to correspond to cDNAs that encoded a full length GATA-5 protein.
GATA-5 mRNA was observed in stomach and all small intestine segments. It was absent from cecum, colon, liver and heart. A 3.2 kb GATA-6 mRNA was found in all small intestine sections, stomach, cecum, colon and heart and was absent from liver. A phosphorimager quantitation of these signals is shown in Figure 6B . As both GATA-5 mRNAs observed in the intestine contain the entire coding region, these bands were quantitated and added together. In all small intestinal regions GATA-6 is expressed at a relatively uniform low level. In the regions encompassing the duodenum (D), proximal jejunum (PJ), and the distal jejunum (DJ), GATA-4 mRNA is the predominant mRNA species. In more distal segments, GATA-4 mRNA levels drop dramatically such that in the distal ileum (I) GATA-4 and GATA-6 are expressed at similar levels and GATA-5 is the predominant mRNA. GATA-5 mRNA levels are lowest in the proximal portions of the small intestine and show an increase distally, especially in ileum.
Therefore, while each GATA mRNA was detected in all sections of the small intestine, highlevel expression of GATA-4 and GATA-5 appear to be complementary to one another along the length of the mouse small intestine. . Therefore, PDX-1 likely contributes significantly to the tissue specificity of the duodenal enhancer. However, evidence indicates that PDX-1 alone is insufficient to activate the enhancer (17). This is not surprising, considering our knowledge of the combinatorial factor requirements of most enhancers and the multiple footprints observed in the enhancer core.
Mutation of specific protein binding sites in the duodenal enhancer does not
The evidence presented here indicates that the GATA sites identified in the enhancer also play a critical role in its function. Mutation of these sites that prevented GATA factor binding severely crippled enhancer function in vivo, and in some transgenic mouse lines essentially destroyed it. There are some discernable differences from previous transgenic mouse studies in which the enhancer module was deleted or specifically mutated. The ability to distinguish these 20 differences is due in part to the exquisite sensitivity of the CAT reporter assay, the number of wild type lines assayed, and the full penetrance of the wild type transgene. The residual duodenal CAT activity in the GATA mutant transgenic mice, although quite low, is higher than that observed for the PDX mutant mice or Denhancer mice that contain a small deletion of the entire enhancer core region (15, 17). The mean normalized duodenal CAT value in ten PDX mutant lines is 0.5 units (excluding line 3 that shows generalized activation in all tissues). In the seven lines of Denhancer mice, where expression is presumably driven only by the ADA promoter, the normalized duodenal CAT value is also 0.5 units. The mean value for GATA mutant mice is 90 units, almost 200 times higher. Even without the unusually high value from line 1, the GATA mutant mean value would be 16 units (over 30 times higher). In addition, some residual duodenal specificity is seen in the GATA mutant mice that is not observed in the PDX mutant mice or Denhancer mice. In five of the ten GATA mutant lines, duodenum is the highest expressing tissue. These are the lines with highest residual duodenal CAT activity (lines 1, 3, 4, 6, and 7). Duodenum was the highest expressing tissue among the nine tissues surveyed in only two of the seventeen PDX mutant mice and Denhancer mouse lines. Therefore, while mutation of the GATA binding sites had a dramatic effect on enhancer function in vivo, some residual duodenal-specific activation was observable. This was most clearly evident in GATA mutant line 1, where duodenal expression was over 10% of the wild type mean and just outside the wild-type's broad normal range. These results suggest that while GATA-4 serves as a strong activator from this enhancer, it may not be involved in its duodenal specificity. Among the three GATA family members expressed in the small intestinal epithelium, our EMSA studies indicate that the ADA enhancer specifically binds GATA-4 in duodenal nuclear extracts. This is somewhat surprising since our messenger studies show that GATA-5 and GATA-6 are also transcribed in duodenum. The Northern blot results indicate GATA-4 mRNA is the predominate species in the duodenum, where it is at least four to five times higher than either GATA-5 or GATA-6 mRNA. This predominance might explain most, but not all of the GATA-4 specificity. Binding-site selectivity does not play a role, since a GATA consensus 22 oligonucleotide that can bind all GATA family members also binds only GATA-4 in the duodenal nuclear extracts ( Figure 2D and data not shown). One possible, but unlikely explanation might be instability of GATA-5 and -6 in the extracts. Perhaps a more likely explanation is specific modification or sequestration of the proteins. GATA-4 has been shown to be serine-phosphorylated and this modification has been shown to enhance both its binding activity and its transcriptional potency (11, 34, 43). It has been proposed that this phosphorylation plays an important regulatory role in GATA-4 function in cardiomyocytes. It is unknown whether any specific non-nuclear localization or sequestration of GATA proteins occurs in intestinal cells. This is a relevant question since the EMSAs were performed with nuclear extracts, not whole cell extracts. It is also possible that translational efficiency plays a role, affecting the relative level of GATA proteins compared to mRNA levels. Additional studies are under way to clarify which, if any, of these possibilities play a role in determining the specificity of the ADA enhancer for GATA-4.
In a recent publication examining regulation of the sucrase-isomaltase (SI) gene, it was reported that GATA-4 binds the promoter of this gene and plays a combinatory role with Cdx2
and HNF-1a in the time-and position-dependent regulation of this gene in intestine (8). In a result that is strikingly similar to our results with the ADA enhancer, their binding studies showed that GATA sites in the SI promoter specifically bound GATA-4 from nuclear extracts of intestinal epithelial cells, and not GATA-5 or -6. They do not identify a specific segment of intestine as the source of the nuclear extracts. Expression of the SI gene is dramatically induced at the suckling-weanling transition in mice, in a pattern very similar to that of ADA. Along the A/P axis the expression pattern of SI is quite different from the predominantly duodenal activation of ADA. SI is broadly expressed along the small intestine with highest levels in 23 jejunum, but significant levels in ileum and duodenum. In light of these similarities and differences in expression patterns for ADA and SI, it is an important observation that the intestine-specific regulatory regions of both specifically bind GATA-4, not GATA-5 or -6. The effect of site-specific mutation of the SI promoter GATA site in vivo (such as in transgenic mice)
has not yet been reported. The keys to which GATA factor functions in the regulation of a particular gene within an intestinal epithelial cell in vivo are likely the relative levels of transcription of the GATA factor genes, the localization and activation state of each GATA protein, and perhaps the context of the promoter or enhancer where the GATA binding site is Recently, microarray technology was used to survey expression of over 8000 thousand genes in segments of adult mouse gastrointestinal tract, from stomach to distal colon (4). The cDNAs from over 500 genes showed elevated expression in one or more segments, and most of these genes displayed sharp segmental expression boundaries. The majority of these boundaries were at anatomically defined locations along the A/P axis. Computer analysis and comparison of putative regulatory regions indicated that a number of genes might be coordinately regulated.
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Basic analysis of regulatory regions such as the ADA duodenal-specific enhancer, and the factors that function there, will be important to elucidating how such global control is accomplished. Multiple hypersensitive sites are indicated with arrows labeled A-G, with HS-D, the region that contains the duodenal enhancer shown in bold. HS-G was initially identified as an individual site (16), but due to an increased time of electrophoresis, it has resolved into multiple bands.
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